Improving Thinking in Everyday Life After Covid-19
Covid-19, Cognitive Impairment
About this trial
This is an interventional treatment trial for Covid-19
Eligibility Criteria
Inclusion Criteria:
- presence of cognitive impairment due to Covid-19 infection
- mild-to-moderate general cognitive impairment as determined by a Montreal Cognitive Assessment (MOCA) score between 10-25
- at least 3 months after positive status for Covid-19
- 18 years or older
- medically stable
- sufficiently fit, from both a physical and mental health perspective, to take part in study
- adequate sight and hearing to complete UFOV test
- adequate thinking skills, e.g., ability to follow directions, retain information, to complete UFOV and CTAL, as marked by judgement of the screener that the candidate is able to adequately complete the UFOV and CTAL
- reside in the community (as opposed to a hospital or skilled nursing facility)
- able to travel to laboratory on multiple occasions
- caregiver available
Exclusion Criteria:
- cognitive impairment due to a developmental disability, psychiatric disorder, or substance abuse
Sites / Locations
- University of Alabama at BirminghamRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Immediate Treatment
Delayed Treatment
The treatment will have 3 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is training following shaping principles on simulated instrumental activities of daily living (IADL), such as making a telephone call or generating a shopping list, in the treatment setting. Shaping involves progressively increasingly the complexity of a task in incremental steps as a participant gains mastery. Frequent, positive feedback is another important aspect of shaping. The third component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily
Participants in this arm will receive testing on the same schedule as the Immediate Treatment up to six-month followup. Delayed Treatment participants will not receive any treatment from the study during this period but will permitted to receive any healthcare that is available on a clinical basis. After six-month followup, participants in this arm will be crossed over to receive the experimental treatment.